DEFLECT I: Keystone Heart Embolic Deflection Trial

NCT ID: NCT01448421

Last Updated: 2020-09-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-03-31
• Study Completion Date: 2014-01-31

Brief Summary

This is a research study using the Keystone Heart Embolic Deflection Device and involving patients with aortic stenosis (a disease of the aortic valve), to be treated with Transcatheter Aortic Valve Replacement (TAVR).

The TAVR procedure consists in replacing the diseased aortic valve by a new artificial valve. The new valve is put into place using a long, thin tube called a catheter that is inserted into a small incision (cut) in the patient's groin and threaded through his/her arteries up to the heart.

Detailed Description

This is a research study using the Keystone Heart Embolic Deflection Device and involving patients with aortic stenosis (a disease of the aortic valve), to be treated with Transcatheter Aortic Valve Replacement (TAVR).

The TAVR procedure consists in replacing the diseased aortic valve by a new artificial valve. The new valve is put into place using a long, thin tube called a catheter that is inserted into a small incision (cut) in the patient's groin and threaded through his/her arteries up to the heart.

During the TAVR procedure, there is a risk that an abnormal particle (called embolism) could break off from inside the arteries and travel to the brain. The embolism could be made of clumps of blood (clots), air, part of your body tissue, or part of a medical device. If the embolism is carried through the blood to the brain, it could cause a stroke or other neurological (brain) problems. A stroke happens when blood flow to a part of the brain is blocked, causing brain cells to die.

The Keystone Heart Embolic Deflection Device has been developed to prevent an embolism from going to the brain and causing a stroke or other brain damage. The device is a wire mesh filter that covers the vessels that carry blood to brain, deflecting any any blood clots or other materials away from the patient's brain and towards the lower body, where they are less likely to cause harm.

Conditions

Aortic Stenosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Keystone Heart Embolic Deflection Device

Protected Transcatheter Aortic Valve Replacement

Group Type: EXPERIMENTAL

Keystone Heart Embolic Deflection Device

Intervention Type: DEVICE

The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.

Interventions

Keystone Heart Embolic Deflection Device

The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. The patient must be ≥18 years of age.

2. Patient meets indications for TAVR procedure.

3. The patient is willing to comply with protocol-specified follow-up evaluations.

4. The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee or Institutional Review Board.

Exclusion Criteria

1. Patients undergoing TAVR via the trans-axillary, subclavian, or direct aortic route

2. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test.

3. Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure (according to definition) or AMI >72 hours preceding the index procedure, in whom creatine kinase and creatine kinase have not returned to within normal limits at the time of procedure.

4. Patients who are currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain.

5. Patients with impaired renal function (estimated Glomerular Filtration Rate [estimated Glomerular Filtration Rate] <30, calculated from serum creatinine by the Cockcroft-Gault formula)

6. Patients with a platelet count of <100.000 cells/mm³ or > 700.000 cells/mm³ or a white blood cell < 3000 cells/mm³ within 7 days prior to index procedure.

7. Patients with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse transfusion.

8. Patients who have received any organ transplant or are on a waiting list for any organ transplant.

9. Patients with known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation or is associated with a life expectancy of less than one year.

10. Patients with known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated.

11. Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months.

12. Patients with an active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 6 months.

13. Patients presenting with cardiogenic shock.

14. Patients with severe peripheral arterial disease that precludes 9 French sheath vascular access.

15. Patients with documented friable or mobile atherosclerotic plaque in the aortic arch.

16. Patients with contraindication to cerebral MRI.

17. Patients who have a planned treatment with any other investigational device or procedure during the study period

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Keystone Heart

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Mullen, Md.

Role: PRINCIPAL_INVESTIGATOR

The Heart Hospital, London, UK

References

Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, Hildick-Smith D, Meller SM, Gambone L, den Heijer P, Margolis P, Voros S, Lansky AJ. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention. 2015 May;11(1):75-84. doi: 10.4244/EIJY15M04_01.

Reference Type: DERIVED

PMID: 25868876 (View on PubMed)

Other Identifiers

DEFLECT I

Identifier Type: -

Identifier Source: org_study_id